Abstract:Purpose: Mutation of the ATM gene may be associated with enhanced radiosensitivity and increased radiation-induced morbidity. Denaturing high performance liquid chromatography (DHPLC) is a powerful new technique proven to be sensitive and accurate in the detection of missense mutations, as well as small deletions and insertions. We screened female breast cancer patients for evidence of ATM gene alterations using DHPLC. This study attempted to determine whether breast cancer patients who develop severe radiotherapy (RT)-induced effects are more likely to possess ATM mutations than patients who display normal radiation responses. Methods and materials: Forty-six patients with early-stage breast carcinoma underwent limited surgery and adjuvant RT. DNA was isolated from blood lymphocytes, and each coding exon of the ATM gene was amplified using polymerase chain reaction. Genetic variants were identified using DHPLC by comparing test patterns with a known wild-type pattern. All variants were subjected to DNA sequencing and compared with wild-type sequences for evidence of a mutation. A retrospective review was performed, and the Radiation Therapy Oncology Group/European Organization for Research and Treatment of Cancer acute and late morbidity scoring schemes for skin and subcutaneous normal tissues were applied to quantify the radiation-induced effects. Results: Nine ATM mutations were identified in 6 patients (8 novel and 1 rare). The median follow-up was 3.2 years (range 1.3-10.3). A significant correlation between ATM mutation status and the development of Grade 3-4 subcutaneous late effects was found. All 3 of the patients (100%) who manifested Grade 3-4 subcutaneous late sequelae possessed ATM mutations, whereas only 3 (7%) of the 43 patients who did not develop this form of severe toxicity harbored an ATM mutation (p = 0.001). One ATM mutation carrier developed Grade 4 soft tissue necrosis after RT and required hyperbaric oxygen. All 3 patients manifesting Grade 3-4 late subcutaneous responses in fact harbored 2 ATM mutations. In contrast, none of the 3 ATM carriers who had a single mutation developed a severe subcutaneous reaction. ATM mutation status did not predict for a significant increase in early effects. Of the 23 patients with Grade 2-3 moist desquamation, 4 (17%) had an ATM mutation compared with 2 (9%) of 23 patients without desquamation (p = 0.7). Conclusion: Possession of an ATM mutation, particularly when 2 are present, may be predictive of an increase in subcutaneous late tissue effects after RT for breast cancer and may subsequently prove to be a relative contraindication to standard management. These patients may be better served with reduced doses of radiation. Equivalent local control remains to be tested, but this germline alteration may radiosensitize normal tissues, as well as the tumor itself. DHPLC is effective in the identification of these patients. A larger study is required to confirm these findings.

Alteration of the ATM Gene Occurs in Gastric Cancer Cell Lines and Primary Tumors Associated with Cellular Response to DNA Damage

Mutation Analysis of the Atm Gene in Two Chinese Patients with Ataxia Telangiectasia

Mutation at Intronic Repeats of the Ataxia-Telangiectasia Mutated (ATM) Gene and ATM Protein Loss in Primary Gastric Cancer with Microsatellite Instability

Expression of ATM gene in human gastric carcinoma cell lines and cellular responses to DNA damage

Expression status of ataxia-telangiectasia-mutated gene correlated with prognosis in advanced gastric cancer.

ATM Polymorphisms Are Associated with Radiosensitivity for Patients with Esophageal Squamous Cell Carcinoma Underwent Preoperative Radiation Therapy

Abstract 1620: ATR Inhibition for the Treatment of ATM-deficient Gastric Cancer

Expression patterns of theATM gene in mammary tissues and their associations with breast cancer survival

The landscape of ATM alteration in Chinese solid tumor patients.

Variation of ATM Protein Expression in Response to Irradiation of Lymphocytes in Lung Cancer Patients and Controls.

Dual Roles of ATM in the Cellular Response to Radiation and in Cell Growth Control.

Discovery of a Pathogenic Variant Rs139379666 (p. P2974L) in ATM for Breast Cancer Risk in Chinese Populations

P1.03-25 the Frequency and Prognosis of ATM Mutations in Chinese Non-Small-Cell Lung Cancer Patients

ATM mutations in female breast cancer patients predict for an increase in radiation-induced late effects

ATM sequence variants associate with susceptibility to non-small cell lung cancer.

Genomic analysis reveals somatic mutations of ATM gene in DNA repair confer exceptional target lesion response to radiation therapy.

Phenotypic consequences of somatic mutations in the ataxia-telangiectasia mutated gene in non-small cell lung cancer

Prevalence and Characterization of ATM Germline Mutations in Chinese BRCA1/2-negative Breast Cancer Patients

Gene-environment Interaction for Polymorphisms in Ataxia Telangiectasia-Mutated Gene and Radiation Exposure in Carcinogenesis: Results from Two Literature-Based Meta-Analyses of 27120 Participants

Abstract B42: ATM deficiency sensitizes gastric cancer cells to the PARP inhibitior olaparib

The Effects of ATM on Cell Cycle after Irradiation